United States Patent 9,205,082 Scope & Claim Map: Sustained-Release Oral Opioid Agonist/Naloxone Abuse-Deterrent Formulations
Patent 9,205,082 claims sustained-release oral opioid agonist/naloxone combinations where naloxone is dosed to be therapeutically compatible for analgesia at label doses but aversive in physically dependent subjects when abused at higher doses, with explicit dose ranges and antagonist-to-agonist ratio constraints. The estate is claim-anchored to (1) an abuse-deterrent performance criterion (aversive at higher abuse doses in physically dependent subjects) and (2) a “no analgesic enhancement” requirement in opioid-naive/without antagonist administration contexts, plus (3) sustained release and once- or twice-daily dosing.
What is US Patent 9,205,082 claiming (scope, elements, and infringement touchpoints)?
Core claim set (independent claim focus):
-
Claim 1 is the primary product claim for a sustained-release oral dosage form containing:
- an opioid agonist selected from oxycodone and its pharmaceutically acceptable salts, with the agonist present in an amount defined equianalgesic to several hydrocodone/hydromorphone/morphine/tramadol ranges;
- an opioid antagonist selected from naloxone (or salts);
- a sustained release carrier containing both agonist and antagonist;
- a specific functional abuse-deterrence and performance profile:
- the antagonist/agonist ratio provides analgesic effectiveness when administered orally;
- but is aversive in physically dependent humans when abused at a higher dose than the therapeutically effective dose;
- and maintains analgesic effect without increasing analgesic efficacy of the opioid agonist relative to the same therapeutic dose of agonist without the antagonist;
- dosing frequency: once daily or twice daily.
-
Claim 11 is the parallel method claim: preventing oral abuse by making the sustained-release oral dosage form with the same abuse-deterrent functional constraints.
-
Claims 15 and 21-ish line cover treating pain by administering claim 1’s dosage form.
Claim 1 dependency breadth:
- Dependent claim 2 tightens the aversive threshold to abuse at about 2–3× therapeutically effective dose in physically dependent addicts.
- Dependent claim 3 optionally layers additional non-opioid analgesic/adjunct classes (NSAID/COX-2 inhibitor, acetaminophen, aspirin, NMDA antagonists, antitussives, expectorants, decongestants, antihistamines and mixtures).
- Dependent claims 5–7 and 13–14 impose equiantagonistic ratio constraints tied to naltrexone equivalence relative to oxycodone, with two nested ratio ranges.
Independent-claim functional requirements create a “performance claim” problem for generics:
Infringement is not just compositional; it is tied to:
- the antagonist-to-agonist ratio (including naltrexone-equivalency constraints);
- the abuse-dose-dependent aversive effect in physically dependent subjects; and
- the absence of analgesic efficacy increase relative to the opioid agonist alone at the same therapeutic dose.
Element-level claim chart (Claim 1)
| Claim 1 element |
What it requires (per text) |
Practical infringement risk area |
| Sustained-release oral dosage form |
“sustained release oral dosage form” administered orally |
Formulation design and release profile |
| Opioid agonist |
opioid agonist selected from oxycodone and salts |
If a product uses other agonists, scope narrows to oxycodone |
| Agonist amount |
equianalgesic to ranges of hydrocodone/hydromorphone/morphine/tramadol |
Dose-range engineering to avoid literal ranges |
| Opioid antagonist |
naloxone and salts |
Switch antagonist or omit naloxone avoids scope |
| Carrier |
sustained release carrier containing agonist and antagonist |
Physical separation or different carrier concept can matter |
| Therapeutic analgesia |
analgesically effective when administered orally |
Infringement is not defeated by labeling endpoints alone |
| Abuse deterrence |
aversive in physically dependent human subjects when abused at higher dose |
Requires demonstration of aversive profile (and “physically dependent” subject condition) |
| “No analgesic enhancement” |
maintains analgesic effect but does not increase analgesic efficacy of agonist relative to same dose without antagonist |
Line-of-comparison requirement for efficacy equivalence |
| Dose frequency |
administrable once-a-day or twice-a-day |
Extended release schedule constraint |
Which dosage forms and release profiles are within scope?
Claim 1 requires a “sustained release oral dosage form” with a sustained-release carrier containing both components. That language tends to target:
- oral tablets/capsules with controlled release matrices, and
- delivery systems where the antagonist is co-delivered such that abuse-dose exposure is aversive.
Once vs twice daily:
The claim is explicit that the dosage form is administrable twice-a-day or once-a-day. A formulation intended for more frequent dosing is positioned outside literal scope, though doctrine-of-equivalents issues would turn on jurisdiction-specific analysis.
Parenteral abuse is expressly considered in dependent claims (9–10):
- Claim 9–10 cover aversiveness when parenterally abused at higher dose, and at 2–3× higher dose. That expands the functional abuse-deterrence narrative beyond oral misuse, but the claimed product remains an oral sustained-release form.
What opioid agonists and antagonist combinations are covered?
Agonist restriction:
The independent claim’s composition anchor is “opioid agonist selected from oxycodone and salts.” The equianalgesic language lists hydrocodone, hydromorphone, morphine, and tramadol ranges as reference conversions, but the controlled species is oxycodone.
Antagonist restriction:
The antagonist is naloxone (or salts). Dependent ratio constraints use naltrexone equivalency as a conversion framework.
Optional add-on non-opioid drugs:
Claim 3 allows combination with non-opioid drugs from a list that includes:
- NSAID, COX-2 inhibitors,
- acetaminophen, aspirin,
- NMDA receptor antagonists or agents blocking intracellular consequences of NMDA activation,
- and several respiratory/allergy classes (antitussive, expectorant, decongestant, antihistamine).
This matters because a manufacturer can potentially design an opioid/naloxone product plus adjuncts. The claim does not appear to require the adjuncts; it optionally broadens product space when they are present.
What does the “abuse is aversive” requirement mean legally in the claim?
The claims repeatedly require that the opioid agonist/naloxone combination:
- is analgesically effective in intended oral use; and
- becomes aversive in physically dependent human subjects when abused at a higher dose; and
- preserves analgesic effect but does not increase analgesic efficacy of the opioid agonist compared to agonist alone at the same therapeutic dose.
Key legal leverage:
- “Physically dependent human subjects” inserts a specific physiological/clinical condition into the claim language.
- “Aversive experience” is functional and performance-based, not purely chemical.
- “Higher dose than said therapeutically effective dose” is relative, so it ties to the reference therapeutic dose used in the same product performance characterization.
- “Does not increase analgesic efficacy” forces a comparison to a comparator regimen: agonist alone at the same therapeutic dose.
For a challenge to infringement, a generic entrant can try to show differences in:
- antagonist-to-agonist ratio,
- release kinetics affecting antagonist availability under misuse conditions,
- and whether abuse-dose exposure yields aversion in physically dependent individuals as defined.
For a patentee, these functional elements frame the evidentiary burden around abuse-deterrence and analgesic profile comparisons.
What specific naltrexone-to-oxycodone ratio ranges are claimed?
Claims 5–7 and 13–14 define ratios using equiantagonistic amount of naltrexone relative to the oxycodone amount.
Ratio constraints appearing in the claims
| Claim |
Ratio expression |
Range |
| Claim 5 |
naltrexone-equivalent to oxycodone |
0.037:1 to 0.296:1 |
| Claim 6 |
narrowed range |
0.056:1 to 0.222:1 |
| Claim 13 |
mirrors claim 5 |
0.037:1 to 0.296:1 |
| Claim 14 |
mirrors claim 6 |
0.056:1 to 0.222:1 |
Scope implication:
A product that uses naloxone but falls outside these antagonist-to-agonist ratios (as converted via the claim’s equiantagonistic framework) risks falling outside literal scope of those dependent claims. Independent claim 1 still requires an opioid antagonist ratio that produces the functional abuse-deterrent profile, but dependent claims provide fixed numeric fences.
What are the explicit oxycodone-equianalgesic dose ranges?
Claim 1 provides an oxycodone amount defined by being equianalgesic to multiple reference opioid dosing bands:
| Reference opioid range in claim |
Equianalgesic anchor language |
| Hydrocodone: 8 mg to 50 mg |
oxycodone amount equianalgesic to hydrocodone band |
| Hydromorphone HCl: 2 mg to 64 mg |
oxycodone amount equianalgesic to hydromorphone band |
| Morphine: 2.5 mg to 800 mg |
oxycodone amount equianalgesic to morphine band |
| Tramadol: 25 mg to 800 mg |
oxycodone amount equianalgesic to tramadol band |
Dependent claim 22–25 isolate these bands by referencing the oxycodone amount more explicitly. Claims 26–29 parallel the same dosing range constraints in the method claim line.
Practical note for claim mapping:
These ranges are broad and contain multiple extreme endpoints (e.g., morphine and tramadol up to 800 mg). Literal avoidance by dose-band selection may be harder than with narrower fixed mg targets, but the claim still ties literal scope to an “equianalgesic” conversion.
How are oral abuse prevention and treating pain claims drafted?
Method for preventing oral abuse (Claim 11)
Claim 11 mirrors claim 1 but is framed as:
- preparing the sustained-release oral dosage form comprising the opioid agonist and antagonist in the sustained release carrier, at the functional ratio profile and dose frequency.
It adds functional constraints tied to preventing oral abuse by achieving aversive misuse effects without analgesic enhancement in non-abused conditions.
Method for treating pain (Claim 15)
Claim 15 is a classic administration claim:
- administering the claim 1 oral dosage form to a patient in need of pain treatment.
This can matter in enforcement because it can reach downstream prescribing and use, subject to jurisdiction and claim construction.
Dependent claims 16–17 reintroduce the numeric ratio constraints (naltrexone-equivalent to oxycodone).
What formulations and design-arounds are most likely outside claim scope?
Based on the textual fences in the claims:
-
Switch the opioid agonist away from oxycodone
The independent claim says the opioid agonist is selected from oxycodone and salts. A different agonist (even within the same “class” of opioids) is positioned outside literal scope.
-
Switch the antagonist away from naloxone
Replacing naloxone with another antagonist (e.g., another partial agonist/antagonist) can avoid literal infringement because the claims name naloxone.
-
Fail the functional abuse-deterrent performance criteria
Even with oxycodone and naloxone present, a product that does not meet:
- aversive experience in physically dependent subjects under abuse at higher doses, or
- “no increase” analgesic efficacy versus agonist alone at the same therapeutic dose
can be argued outside claim reach if the claim construction requires meeting those performance elements.
-
Release profile not “sustained release” or dosage frequency not once/twice daily
A different release mechanism or dosing schedule is a potential literal avoidance vector.
-
Alter the antagonist-to-agonist ratio outside the numeric dependent ranges
Dependent claims 5–7 and 13–14 include explicit windows. If a product’s equiantagonistic ratio does not fall within these windows, those dependent claims are harder for the patentee to assert.
How strong is the patent estate position for US 9,205,082 on abuse-deterrent opioids?
With only claim text provided, the strength analysis can be limited to what is structurally evident in the claims themselves:
Strength drivers built into the claim:
- Explicit numeric ratio windows (naltrexone-equivalent to oxycodone) in dependent claims.
- Tied functional abuse deterrence to physically dependent human subject aversion, not just pharmacokinetic changes.
- Analgesic efficacy non-enhancement comparator requirement that can be tested relative to a matched-dose agonist regimen.
Potential vulnerability drivers built into the claim:
- Broad equianalgesic dose conversions spanning very wide ranges, which can complicate consistent claim charts but also makes it easier for entrants to argue their dose regimen falls outside the intended conversion basis.
- Comparator-dependent efficacy requirement (“does not increase analgesic efficacy of said opioid agonist relative to the same therapeutic dose … without said opioid antagonist”) can be fact-heavy and potentially contentious in litigation over how “same therapeutic dose” and “increase” are determined.
What Orange Book status, FDA pathway, and Paragraph IV landscape exist for this patent?
No Orange Book listing, FDA reference product, application number, patent listing date, or paragraph IV litigation record can be derived from the patent claim text alone. Without those identifiers, any status statement would be unsupported.
Accordingly, the claim text does not provide:
- the drug product name linked to US 9,205,082,
- the reference listed drug (RLD),
- whether the patent is listed for formulation vs method-of-use,
- any ANDA/BLA submissions challenging the patent, or
- any settlement/consent decree timeline.
What litigation outcomes, settlements, or generic entry risks attach to US 9,205,082?
The claims provided do not identify:
- any parties,
- case captions,
- jurisdictions (EDTX, SDNY, etc.),
- asserted or dismissed claims,
- injunction or settlement terms,
- or any specific generic challengers.
Therefore, a litigation-risk assessment tied to the patent cannot be completed from the claim text alone.
Key takeaways
- US 9,205,082 is an abuse-deterrent focused patent on sustained-release oral oxycodone/naloxone products with once- or twice-daily dosing.
- The claim scope is driven by three coupled constraints: sustained release, antagonist-to-agonist ratio expressed via naltrexone equivalency (in dependent claims), and a functional performance profile requiring aversiveness in physically dependent subjects during higher-dose abuse while avoiding analgesic efficacy enhancement versus agonist alone at the same therapeutic dose.
- Product design-around vectors most supported by the textual claim language are: using a non-oxycodone agonist, using a non-naloxone antagonist, changing dosing frequency/release format, and failing the aversive/no-analgesic-enhancement performance criteria.
FAQs
-
Can a sustained-release oxycodone/naloxone product avoid US 9,205,082 by using a different sustained-release carrier?
Carrier identity is part of the claim through “sustained release carrier that contains” both components, so a carrier that physically segregates or eliminates joint sustained release may be relevant, depending on how “contains” and release profile are construed.
-
Does the patent cover oxycodone/naloxone abuse deterrence when misused by injection?
Dependent claims include aversiveness upon parenteral abuse at higher doses and at about 2–3× in physically dependent subjects.
-
If a product’s antagonist-to-agonist ratio is outside 0.037:1 to 0.296:1, does it avoid the dependent claims?
It avoids those dependent numeric claim embodiments, but the independent claim still requires a ratio that achieves the defined functional abuse-deterrence and non-enhancement effects.
-
Do the claims require naloxone to be equianalgesic to naltrexone?
The ratio is expressed using equiantagonistic amounts of naltrexone relative to oxycodone in the dependent claims.
-
Are non-opioid adjuncts mandatory to infringe?
No. Non-opioid adjuncts are recited in a dependent claim as optional “further comprising” categories.
References
- United States Patent 9,205,082. Claims provided in prompt.
